# Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy

> **NCT01722513** · PHASE4 · UNKNOWN · sponsor: **Shanghai 10th People's Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Kidney Diseases
- Diabetes Mellitus
- Acute Kidney Injury
- Kidney Failure, Chronic
- Renal Insufficiency

## Interventions

- **DRUG:** Alprostadil ﹠control

## Key facts

- **NCT ID:** NCT01722513
- **Lead sponsor:** Shanghai 10th People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-11
- **Primary completion:** 2013-11
- **Final completion:** 2014-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2012-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01722513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01722513, "Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT01722513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*